Senti Biosciences Holdings, Inc. — Form 8-K

Senti Biosciences amended its Securities Purchase Agreement (dated April 27, 2026) to add NSG BioInnovation Fund, L.P. as a new investor purchasing $2,000,000 of Additional Notes. Combined with prior tranches, the Lead Investor (CPIF II-7 Limited) has committed $10,000,000 (May 20, 2026) plus $4,000,000 (August 14, 2026), while the new joining buyer commits $2,000,000 (Additional Closing Date set for September 4, 2026). Total potential funding under the agreement reaches $40,000,000 ($10M initial + $30M additional notes capacity). The amendment also confirms that completion of these purchases satisfies the Lead Investor's funding obligations under the July 14, 2026 Merger Agreement with Celadon Partners SPV 35 Limited.